Current role of interferon in hairy cell leukemia therapy: a timely decision

Silva, Wellington F; Teixeira, Larissa Lane Cardoso; Rocha, Vanderson; Buccheri, Valéria

doi:10.1016/j.htct.2018.04.004

Cited by 7 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IFN-α has been used to treat hairy cell leukaemia, CML, and myelofibrosis for several years. 169,170 IFNs co-formulation has also been suggested to improve temozolomide therapy by inhibiting the repair enzyme MGMT. 171 Cytokines such as TNF48 and IL2 have also been repurposed, but with limited clinical success due to high toxicity.…”

Section: Drug Repurposing In Oncologymentioning

confidence: 99%

Repurposing: A Potentially Emerging Discipline

Prabhash¹,

Mammen²,

Madhusoodhanan³

et al. 2022

IJPER

View full text Add to dashboard Cite

Drug repurposing is the remodeling of already existing drugs to reduce the time frame, costs, and efforts in developing a new novel drug. This strategy has secured significant momentum in the previous decade. It overcomes the snags and pitfalls in the traditional means of drug discovery. This core research strategy has now become the sole approach to containing many deadly diseases that have no cure in the present. In astound, for pandemics like COVID-19 that is spreading like a wildfire worldwide, large-scale research programs and trials have been carried out to identify and modify existing drugs to counter the novel virus. Thus, this technology of drug repurposing offers a new lease of life, and greatly promotes the progress of the medicine, health, and pharma sectors. The purpose of this study is to understand the current status of drug repurposing in the field of virology, bacteriology, mycology, and oncology for clinical translatability.

show abstract

Section: Drug Repurposing In Oncologymentioning

confidence: 99%

Repurposing: A Potentially Emerging Discipline

Prabhash¹,

Mammen²,

Madhusoodhanan³

et al. 2022

IJPER

View full text Add to dashboard Cite

show abstract

“…However, similar to IFN, IFNcauses adverse side effects that can lead to flu-like symptoms, central nervous system defects, depression, and a 20% chance of developing a secondary cancer [1,12]. IFNhas also been used to increase blood cell counts in patients who suffer from anemia due to infection or as a result from chemotherapy treatments [1,12,75]. Though monotherapy with IFNwas not successful, combination therapy with TKIs or other chemotherapeutics may be a viable treatment option to target LSCs through activation and improved chemosensitivity upon IFNtreatment or by altering the host immune response to LSCs.…”

Section: Ifns and Hematological Cancersmentioning

confidence: 99%

Yin and Yang: The dual effects of interferons on hematopoiesis

Demerdash

Kain

Essers

et al. 2021

Experimental Hematology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…In 1986, the first lab-made IFN was created to treat certain types of cancer. One of the first clinical uses of IFN was to treat a rare form of leukemia, known as hairy cell leukemia, which results from the over-production of mature (and abnormal) B-cells [96][97][98][99].…”

Section: Developing the Concept Of Immune Therapy For Chbmentioning

confidence: 99%

Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical

Akbar

Mahtab

Aguilar

et al. 2021

Exploration of Medicine

View full text Add to dashboard Cite

With the advent of various vaccines and antimicrobial agents during the 20th century, the control and containment of infectious diseases appeared to be a matter of time. However, studies unveiled the diverse natures of microbes, their lifestyle, and pathogenetic potentials. Since the ground-breaking discovery of the hepatitis B virus (HBV) by Baruch Blumberg and the subsequent development of a vaccine in the early 1980s, the main task of the scientific community has been to develop a proper management strategy for HBV-induced chronic liver diseases. In the early 1980’s, standard interferon (IFN) induced a reduction of HBV DNA levels, followed by the normalization of serum transaminases (alanine aminotransferase, ALT), in some chronic hepatitis B (CHB) patients. However, in the course of time, the limitations of standard IFN became evident, and the search for an alternative began. In the late 1980’s, nucleoside analogs entered the arena of CHB treatment as oral drugs with potent antiviral capacities. At the beginning of the 21st century, insights were developed into the scope and limitations of standard IFN, pegylated-IFN as well as nucleoside analogs for treating CHB. Considering the non-cytopathic nature of the HBV, the presence of covalently closed circular DNA (cccDNA) in the nucleus of the infected hepatocytes and HBV-induced immune-mediated liver damages, a new field of CHB management was initiated by modulating the hosts’ immune system through immune therapy. This review will discuss the nature and design of innovative immune therapy for CHB.

show abstract

Current role of interferon in hairy cell leukemia therapy: a timely decision

Cited by 7 publications

References 11 publications

Repurposing: A Potentially Emerging Discipline

Repurposing: A Potentially Emerging Discipline

Yin and Yang: The dual effects of interferons on hematopoiesis

Exploring evidence-based innovative therapy for the treatment of chronic HBV infection: experimental and clinical

Contact Info

Product

Resources

About